Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab +/- Irinotecan in Cetuximab-Refractory Colorectal Cancer
NCT00677924Phase 2Terminated
- Sponsor
- Genmab
- Start
- Apr 2008
- Primary completion
- Apr 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zalutumumab in colorectal cancer (CRC) (2 arms), sponsored by Genmab. Primary endpoint: Number of Participants With Adverse Events at 1 year. Started Apr 2008; status: terminated.
02
Drugs
zalutumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00677924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00677924.